Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.47 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.47 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.47 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 4/20 | 0.42 |
| ▸ | ITK | Q08881 | 3/20 | 0.42 |
| ▸ | IL2 | P60568 | 1/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | PLK4 | O00444 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27098776 | 1.00 | CRBN (0.47) | CRBNIRAK4IRAK1IRAK3CCNC | |
| SCHEMBL27099324 | 0.92 | RAF1 (0.45) | CRBNIRAK4IRAK1IRAK3CCNC | |
| SCHEMBL27098770 | 0.89 | RAF1 (0.45) | CRBNIRAK4IRAK1IRAK3CCNC | |
| SCHEMBL29857405 | 0.89 | RAF1 (0.45) | CRBNIRAK4IRAK1IRAK3CCNC | |
| SCHEMBL27099271 | 0.87 | BRD9 (0.49) | CRBNIRAK4IRAK1IRAK3CCNC | |
| SCHEMBL27099253 | 0.86 | BRD9 (0.47) | CRBNIRAK4IRAK1IRAK3CCNC | |
| SCHEMBL27099338 | 0.86 | CRBN (0.45) | CRBNIRAK4IRAK1IRAK3CCNC | |
| SCHEMBL27098573 | 0.85 | BRD9 (0.47) | CRBNIRAK4IRAK1IRAK3CCNC | |
| SCHEMBL29857558 | 0.85 | BRD9 (0.47) | CRBNIRAK4IRAK1IRAK3CCNC | |
| SCHEMBL29857130 | 0.84 | BTK (0.46) | CRBNIRAK4IRAK1IRAK3CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | CRBN 2/4885IRAK4 4049/4885IRAK1 3749/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CRBN 3/4885IRAK4 3852/4885IRAK1 3587/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | CRBN 2/4885IRAK4 4049/4885IRAK1 3749/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | CRBN 3/4885IRAK4 3811/4885IRAK1 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.